AUS
NZ
UK
CA
USA
IND
Highlights
- ResMed's projected 20.2% earnings growth outpaces the industry average of 15.9%.
- The company boasts impressive 18.1% year-over-year cash flow growth.
Growth stocks are often the focal point of investors looking for exceptional returns, as above-average financial growth allows these stocks to attract significant attention. However, identifying the right growth stock is challenging, as these companies often carry higher risks and volatility. Moreover, betting on a growth story that is nearing its end can lead to considerable losses.
That said, with the help of the Zacks Growth Style Score, investors can now better identify cutting-edge growth stocks. Zacks’ system goes beyond traditional growth metrics, offering a deeper look into a company’s real growth prospects. ResMed (ASX:RMD), a leader in medical products for respiratory disorders, stands out as one of the top growth stock recommendations.
- Earnings Growth: A Key Indicator of Strong Prospects
Earnings growth is often considered the most crucial metric for growth investors. Double-digit earnings growth typically signals strong prospects for a company, often leading to significant stock price gains. ResMed’s historical EPS growth rate is impressive at 12.6%. However, investors should focus on the company’s projected earnings growth, which is expected to hit 20.2% this year. This growth significantly outpaces the industry average of 15.9%, making ResMed a standout in its sector.
This robust earnings growth suggests that ResMed is well-positioned to continue expanding its market share and increasing profitability, providing a solid foundation for future stock price appreciation.
- Cash Flow Growth: Fuel for Expansion
For growth-oriented companies like ResMed, cash flow growth is vital for expanding operations without relying on expensive external funding. Currently, ResMed is experiencing an impressive year-over-year cash flow growth of 18.1%, a figure that far exceeds the industry average of -15.1%. This indicates that the company is not only generating cash but is also doing so at a rate that supports its growth strategies and minimizes financial risks.
Furthermore, looking at the company’s 3-5 year annualized cash flow growth rate of 14.9%, compared to the industry average of 6.1%, underscores the strong financial foundation ResMed has built over time. This consistent cash flow growth enhances its ability to invest in new products and expand its market presence, which could drive future earnings and stock price growth.
- Promising Earnings Estimate Revisions: A Positive Trend
A key factor in determining the future performance of a stock is the trend in its earnings estimate revisions. A positive revision trend suggests that analysts expect the company’s earnings to exceed previous expectations, often leading to upward movement in stock prices. For ResMed, the earnings estimate revisions are moving in a favorable direction, which is a promising sign for investors.
